Show simple item record

dc.contributor.authorMorris-Downes, M
dc.contributor.authorSmyth, E G
dc.contributor.authorMoore, J
dc.contributor.authorThomas, T
dc.contributor.authorFitzpatrick, F
dc.contributor.authorWalsh, J
dc.contributor.authorCaffrey, V
dc.contributor.authorMorris, A
dc.contributor.authorFoley, S
dc.contributor.authorHumphreys, H
dc.date.accessioned2011-03-31T13:20:28Z
dc.date.available2011-03-31T13:20:28Z
dc.date.issued2010-07
dc.identifier.citationSurveillance and endemic vancomycin-resistant enterococci: some success in control is possible. 2010, 75 (3):228-33 J. Hosp. Infect.en
dc.identifier.issn1532-2939
dc.identifier.pmid20363048
dc.identifier.doi10.1016/j.jhin.2010.01.004
dc.identifier.urihttp://hdl.handle.net/10147/126576
dc.description.abstractVancomycin-resistant enterococci (VRE) are prevalent in many Irish hospitals. We analysed surveillance data from 2001 to 2008 in a centre where VRE is endemic. All clinically significant enterococci were tested for susceptibility to vancomycin. All intensive care unit admissions were screened on admission and weekly thereafter. Interventions included isolating/cohorting VRE patients, monthly prevalence surveys of VRE patients, the introduction of an electronic alert system, programmes to improve hand and environmental hygiene, and the appointment of an antibiotic pharmacist. There was a significant increase in the number of positive VRE screening samples from 2001 (1.96 patients with positive VRE screens per 10 000 bed-days) to 2006 (4.98 per 10 000 bed-days) (P < or = 0.001) with a decrease in 2007 (3.18 per 10 000 bed-days) (P < or = 0.01). The number of VRE bloodstream infections (BSI) increased from 0.09 BSI per 10 000 bed-days in 2001 to 0.78 per 10 000 bed-days in 2005 (P < or = 0.001) but decreased subsequently. Linear regression analysis indicated a significant association between new cases of VRE and non-isolated VRE patients, especially between May 2005 and December 2006 [P=0.009; 95% confidence interval (CI): 0.08-0.46] and between May 2005 and December 2008 (P = 0.008; 95% CI: 0.06-0.46). Routine surveillance for VRE together with other measures can control VRE BSI and colonisation, even where VRE is endemic, and where facilities are constrained.
dc.language.isoenen
dc.subject.meshBacteremia
dc.subject.meshCarrier State
dc.subject.meshCross Infection
dc.subject.meshEndemic Diseases
dc.subject.meshEnterococcus
dc.subject.meshGram-Positive Bacterial Infections
dc.subject.meshHospitals
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshInfection Control
dc.subject.meshIreland
dc.subject.meshSentinel Surveillance
dc.subject.meshVancomycin Resistance
dc.titleSurveillance and endemic vancomycin-resistant enterococci: some success in control is possible.en
dc.typeArticleen
dc.contributor.departmentDepartment of Microbiology, Beaumont Hospital, Dublin, Ireland.en
dc.identifier.journalThe Journal of hospital infectionen
dc.description.provinceLeinster
html.description.abstractVancomycin-resistant enterococci (VRE) are prevalent in many Irish hospitals. We analysed surveillance data from 2001 to 2008 in a centre where VRE is endemic. All clinically significant enterococci were tested for susceptibility to vancomycin. All intensive care unit admissions were screened on admission and weekly thereafter. Interventions included isolating/cohorting VRE patients, monthly prevalence surveys of VRE patients, the introduction of an electronic alert system, programmes to improve hand and environmental hygiene, and the appointment of an antibiotic pharmacist. There was a significant increase in the number of positive VRE screening samples from 2001 (1.96 patients with positive VRE screens per 10 000 bed-days) to 2006 (4.98 per 10 000 bed-days) (P < or = 0.001) with a decrease in 2007 (3.18 per 10 000 bed-days) (P < or = 0.01). The number of VRE bloodstream infections (BSI) increased from 0.09 BSI per 10 000 bed-days in 2001 to 0.78 per 10 000 bed-days in 2005 (P < or = 0.001) but decreased subsequently. Linear regression analysis indicated a significant association between new cases of VRE and non-isolated VRE patients, especially between May 2005 and December 2006 [P=0.009; 95% confidence interval (CI): 0.08-0.46] and between May 2005 and December 2008 (P = 0.008; 95% CI: 0.06-0.46). Routine surveillance for VRE together with other measures can control VRE BSI and colonisation, even where VRE is endemic, and where facilities are constrained.


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record